SillaJen, Inc

Amid continued weakness in general investor sentiment around initial public offerings (IPOs) and venture capital (VC) financings in the sector, South Korean biopharma companies increasingly opted for

2019 was a challenging year for the South Korean pharma and biotech sector. On balance, negative and disappointing news outnumbered positive developments, amid issues regarding the country’s first app

The South Korean regulatory environment for cell and gene therapies is poised to change substantially through a new Cutting Edge Regenerative Medicine and Biologics Act to be introduced next year. But

Initial public offerings in the South Korean biotech sector are poised to recover from a nearly year-long slump, as several companies which have been under investors’ radars are slated to launch IPOs